期刊文献+

糖原累积症Ⅰ型心血管受累的临床分析 被引量:2

Cardiovascular risk profile of patients with glycogen storage disease type Ⅰ
原文传递
导出
摘要 目的 分析糖原累积症Ⅰ型心血管疾病损害的危险因素.方法 收集62 例糖原累积症Ⅰ型患者的临床资料,分析其心脏损害的发生率及可能诱发心血管疾病的高危因素.结果 62例患者中,女性26例,男性36例,平均年龄(8.4±6.9)岁,平均病程(6.7±6.2)年,接受治疗时间(38.3±35.2)个月.其中17.7%的患者有心电图异常,24.2%的患者超声心动图有异常发现;治疗前后患者的血总胆固醇、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇和血尿酸分别为(6.18±2.47)mmol/L与(5.61±1.84)mmol/L,P=0.020;(11.17±9.85)mmol/L与(6.81±5.97)mmol/L,P=0.010;(2.55±1.27)mmol/L与(2.78±1.07)mmol/L,P=0.617;(0.98±0.37)mmol/L与(0.96±0.23)mmol/L,P=0.005;(526.53±127.09)μmol/L与(490.78±129.79)μmol/L,P=0.977.高敏C反应蛋白水平则由治疗前的(2.33±3.30)mg/L升至(3.35±3.39)mg/L,P=0.431.结论 糖原累积症Ⅰ型患者可能是心血管疾病的高危人群,应重视糖原累积症Ⅰ型引起的心血管系统受累及相关的危险因素. Objective To investigate the cardiovascular risk profile in patients with glycogen storage disease (GSD) type Ⅰ.Method The clinical information of 62 patients with GSD type Ⅰ who admitted to Peking Union Medical Hospital were reviewed and the cardiovascular risk profile was analyzed.Results The age of the 26.The median disease duration was (6.7±6.2) years and treatment duration was (38.3±35.2) months. The rate of abnormal change in electrocardiogram and echocardiography was 17.7% and 24.2%, respectively. The serum concentration of total cholesterol(TC), triglyceride(TG), low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and uric acid in patient before and after treatment were (6.18±2.47)mmol/L vs. (5.61±1.84)mmol/L(P=0.020),(11.17±9.85)mmol/L vs. (6.81±5.97)mmol/L(P=0.010),(2.55±1.27)mmol/L vs. (2.78±1.07)mmol/L(P=0.617),(0.98±0.37)mmol/L vs. (0.96±0.23)mmol/L(P=0.005),(526.53±127.09)μmol/L vs. (490.78±129.79)μmol/L(P=0.977), respectively. The high-sensitivity C-reactive protein levels tended to be higher after therapy compared before treatment (2.33±3.30)mg/L vs. (3.35±3.39)mg/L, P=0.431.Conclusion Patients with GSD Ⅰ are associated with an increased risk for cardiovascular disease.
机构地区 中国医学科学院
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2011年第6期508-511,共4页 Chinese Journal of Cardiology
关键词 糖原累积症 心血管疾病 Glycogen storage disease Cardiovascular diseases
  • 相关文献

参考文献13

  • 1Rake JP, Visser G, Labrune P, et al. Glycogen storage disease type s : diagnosis, management, clinical course and outcome. ResuKs ofthe European Study on Glycogen Storage Disease Type I (ESGSD I ). Eur J Pediatr,2002,161(Suppl 1):S20-S34.
  • 2Rake JP, Visser G, Labrune P, et al. Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I ). Eur J Pediatr,2002,161 ( Suppl 1 ) : S112-$119.
  • 3Fayssoil A. Cardiomyopathy in Pompe's disease. Eur J Intern Med, 2008,19:57-59.
  • 4Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med,2005, 352 : 362-372.
  • 5YekeIer E, Dursun M, Emeksiz E, et al. Prediction of premature atherosclerosis by endothelial dysfunction and increased intimamedia thickness in glycogen storage disease types la and Ⅲ. Turk J Pediatr, 2007,49 : 115-119.
  • 6Bernier AV, Correia CE, Hailer MJ,et al. Vascular dysfunction in glycogen storage disease type I . J Pediatr, 2009, 154:588-591.
  • 7Russo G, Leopold JA, Loscalzo J. Vasoactive substances : nitric oxide and endothelial dysfunction in atherosclerosis. Vasc Pharmacol, 2002,38:259-269.
  • 8Fathi R, Marwick TH. Noninvasive tests of vascular function and structure : why and how to perform them. Am Heart J, 2001,141 : 694 -703.
  • 9Ridker PM, MacFadyen J, Libby P, et al. Relation of baseline highsensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the justification for use of statins in prevention: an Intervention Trim Evaluating Rosuvastatin (JUPITER). Am J Cardiol, 2010, 106:204-209.
  • 10Bahadursingh S, Behan'y K, Maharaj K, et al. C-reactive protein: adjunct to cardiovascular risk assessment. West Indian Med J ,2009,58:551-555.

同被引文献61

  • 1王丽苹,何婷婷,崔延飞,王仲霞,景婧,王立福,朱云,孙永强,许文涛,余思邈,桑秀秀,田淼,王睿林.97例糖原累积病的临床及病理特点分析[J].肝脏,2020(12):1326-1329. 被引量:5
  • 2何大可,张建明,邵新华,宋小青,吴静,顾学范.81例遗传代谢病患儿神经系统损害和症状分析[J].上海交通大学学报(医学版),2011,31(10):1444-1447. 被引量:14
  • 3Mayatepek E, Hoffmann B, Meissner T. Inborn errors of carbohydrate metabolism[J]. Best Pract Res Clin Gastroenterol, 2010, 24:607-618.
  • 4Rake JP, ~isser G, Labrune P, et al. Glycogen storage disease type I:diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I)[J]. Eur J Pediatr, 2002, 161(Suppl 1):$20-34.
  • 5Smit GP. The long-term outcome of patients with glycogen storage disease type Ia[J]. Eur J Pediatr, 1993, 152(Suppl 1):$52-55.
  • 6Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the Primary Prevention of Stroke:A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association[J]. Stroke, 2014, 45:3754-3832.
  • 7Fine RN, Podosin R, Donnell GN. Acute hemiplegia in glycogen storage disease type l[J]. Acta Paediatr Scand, 1969, 58:621-624.
  • 8Aydinli N, Tatli B, Caliskan M, et al. Stroke in childhood:experience in Istanbul, Turkey[J]. J Trop Pediatr, 2006, 52:158-162.
  • 9Goulart JM, Yoo JY, Kirchoff-Torres KF, et al. Ischemic stroke in an adult with glycogen storage disease type I[J]. J Clin Neurosci, 2010, 17:1467-1469.
  • 10Berzsenyi MD, Brady BM, O'Donnell C J, et al. Cerebrovascular disease in type 1A glycogen storage disease[J]. J Clin Neurosci, 1998, 5:93-94.

引证文献2

  • 1洪月慧,彭斌,邱正庆.糖原贮积病1型患者卒中风险的研究现状[J].中国卒中杂志,2015,10(10):896-901. 被引量:1
  • 2中国妇幼保健协会出生缺陷防治与分子遗传分会,中国妇幼保健协会儿童早期发展专业委员会,中国妇幼保健协会儿童疾病和保健分会遗传代谢学组,中国医师协会儿科医师分会内分泌遗传代谢学组,中国医师协会儿科医师分会青春期医学专业委员会临床遗传学组及生化学组,中华预防医学会残疾预防与控制专业委员会,中华预防医学会儿童保健分会,北京医学会罕见病分会,深圳罕见病代谢组学精准医学工程研究中心,中华医学会医学遗传学分会生化与代谢学组,中国医师协会医学遗传医师分会临床生化遗传专业委员会,陈永兴,梁黎黎,王晓建,张宏武,邱文娟,张尧.糖原累积病Ⅰa型的诊断治疗和预防专家共识[J].中国实用儿科杂志,2022,37(9):641-649. 被引量:6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部